Literature DB >> 20467450

MicroRNA and drug resistance.

J Ma1, C Dong, C Ji.   

Abstract

Chemotherapy is the preferred treatment for malignancies. However, a successful long-term use of chemotherapy is often prevented by the development of drug resistance. Many mechanisms such as gene mutation, DNA methylation and histone modification have important roles in the resistance of cancer cells to chemotherapeutic agents. Climent suggested miR-125b was involved in the development of drug resistance by microRNA (miRNA) dysregulation. miRNAs are endogenously expressed small non-coding RNAs, which are evolutionarily conserved and function as regulators of gene expression. Much effort has been exerted in analyzing the role of miRNAs in the development of drug resistance in a variety of malignancies. Several research groups have shown that the expressions of miRNAs in chemoresistant cancer cells and their parental chemosensitive ones are different. The molecular targets and mechanisms of chemosensitivity and chemoresistance are also elucidated. This article reviews the functions of miRNAs in the development of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467450     DOI: 10.1038/cgt.2010.18

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  125 in total

1.  MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.

Authors:  Xiao He; Xia Xiao; Lin Dong; Nengbin Wan; Zhengyu Zhou; Hongwu Deng; Xiefu Zhang
Journal:  Tumour Biol       Date:  2014-11-15

Review 2.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

3.  The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells.

Authors:  Mengjia He; Qianni Jin; Cong Chen; Yifeng Liu; Xiangsen Ye; Yulin Jiang; Feihu Ji; Husun Qian; Delu Gan; Shujun Yue; Wei Zhu; Tingmei Chen
Journal:  Oncogene       Date:  2019-04-09       Impact factor: 9.867

4.  Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.

Authors:  Yehua Shen; Yan Pan; Litao Xu; Lianyu Chen; Luming Liu; Hao Chen; Zhen Chen; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2015-02-27

Review 5.  Mitochondrial ROS and cancer drug resistance: Implications for therapy.

Authors:  Imoh S Okon; Ming-Hui Zou
Journal:  Pharmacol Res       Date:  2015-08-11       Impact factor: 7.658

6.  A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.

Authors:  Liqin Du; Robert Borkowski; Zhenze Zhao; Xiuye Ma; Xiaojie Yu; Xian-Jin Xie; Alexander Pertsemlidis
Journal:  RNA Biol       Date:  2013-09-30       Impact factor: 4.652

7.  miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.

Authors:  Shujing Liu; Michael T Tetzlaff; Tao Wang; Ruifeng Yang; Lin Xie; Gao Zhang; Clemens Krepler; Min Xiao; Marilda Beqiri; Wei Xu; Giorgos Karakousis; Lynn Schuchter; Ravi K Amaravadi; Weiting Xu; Zhi Wei; Meenhard Herlyn; Yuan Yao; Litao Zhang; Yingjie Wang; Lin Zhang; Xiaowei Xu
Journal:  Pigment Cell Melanoma Res       Date:  2015-05-16       Impact factor: 4.693

Review 8.  Small non-coding RNA and cancer.

Authors:  Giulia Romano; Dario Veneziano; Mario Acunzo; Carlo M Croce
Journal:  Carcinogenesis       Date:  2017-05-01       Impact factor: 4.944

9.  Pax-5 Inhibits NF-κB Activity in Breast Cancer Cells Through IKKε and miRNA-155 Effectors.

Authors:  Jason Harquail; Nicolas LeBlanc; Carine Landry; Nicolas Crapoulet; Gilles A Robichaud
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-21       Impact factor: 2.673

10.  MicroRNA gene dosage alterations and drug response in lung cancer.

Authors:  Katey S S Enfield; Greg L Stewart; Larissa A Pikor; Carlos E Alvarez; Stephen Lam; Wan L Lam; Raj Chari
Journal:  J Biomed Biotechnol       Date:  2011-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.